Cartesian Therapeutics Unveils Promising Phase 2b Trial Results

Cartesian Therapeutics announced 12-month data showing Descartes-08’s sustained efficacy and safety for MG.
Participants without prior biologic therapies showed significant symptom improvement, supporting Descartes-08’s potential in MG treatment.